The connected drug delivery products are used to address patient’s issues related to disease management protocols, medications, and treatments. Connected drug delivery is one of the emerging solutions equipped with a sensor that facilitates connection and transfer of data to servers/applications via near field communication (NFC), Bluetooth, or cellular networks.
Factors Enhancing the Growth of the Industry
Increasing cases of chronic disorders such as diabetes, asthma, and COPD are the main attributors behind the growth of connected drug delivery technologies. A study conducted by researchers at Tongji Medical College and Huazhong University of Science and Technology, China asserts that the fatalities related to chronic lung diseases have been increased by almost 18%, from 3.3 million in 1990 to 3.9 million in 2017 worldwide. However, several companies operating in connected drug delivery technologies are implementing effective strategies to gain a prime position in the global industry and thus helping in reducing the death rates.
Recent Advances in the Industry
According to a report published by Research Dive , the leading players of connected drug delivery market include Propeller Health, Adherium, BD, West Pharmaceutical Services, F. Hoffmann-La Roche Ltd, Ypsomed AG, Syncro Technology Corp., AptarGroup Inc, Cohero Health, Inc., and Proteus Digital Health.
Unique and smart strategies are being developed by these market players to take the market to another height. The strategies include product innovation and launches, technology and product upgradation, mergers and acquisitions, and partnerships and collaborations.
Some of the recent updates of the market are mentioned below:
- As per a recent update, Propeller Health is cooperating with Novartis to co-package the Propeller digital health platform with recently approved Enerzair Breezhaler. Novartis has developed this product to treat uncontrolled asthma.
- Another news states, Adherium (NZ) Limited, one of the leading player of the market, has initiated a long term partnership with AstraZeneca, a multinational biopharmaceutical company based out of London. The mission behind this partnership is to develop a first-in-world commercial arrangement combining digital health technology with epic inhaler medications to provide better treatment to patients with respiratory conditions.
- LEO Pharma A/S and Portal Instruments has recently made an announcement regarding a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with LEO Pharma’s portfolio of investigational and approved medicines.
Portal needle-free system includes a re-usable, software-controlled handheld injection device and a proprietary, single-use, pre-filled cartridge. In this system, the medicine is injected through a pressurized liquid jet. This is a clinically-proven less painful system compared to a standard needle-based injection.
- Nemera’s Safe’n’Spray smart electronic concept device has achieved the acknowledgement as the “Best Innovation in Drug Delivery Device” at Pharmapack awards in February, 2020.
- Headquartered in USA, AptarGroup, Inc. is a global manufacturer of consumer dispensing, active packaging and drug delivery solutions. Recently, this company has announced a collaboration with Sonmol, a leading Chinese digital respiratory therapeutics company. This collaboration aimed at developing a digital therapies and services platform especially for respiratory diseases.
- In November 2019, LOG pharma, another leading player in the healthcare sector, has announced the launch of a smart device, IoT-enabled ‘ActiveGuard’ connect. This innovative device is primarily developed to address the problem of lack of patient adherence to prescribed medications.
- January 2018, Aptar Group, a pioneer in drug delivery systems provider hold an exhibition at Pharmapack 2018. In this event, the organization exhibited its significant connected healthcare solutions with various patient-friendly features.
With the COVID-19 outbreak, the global connected drug delivery market has experienced a massive progress. Some global leaders in the connected drug delivery devices market are coming forward with strategic initiatives to serve the society with their products and services during the catastrophic time.
For instance, in January 2020, Aptar Pharma, a pioneer in drug delivery systems announced its partnership with Lupin to Launch ADHERO, India’s 1st connected drug delivery device for the COPD (chronic obstructive pulmonary disease) and asthma suffering patients. The device is Bluetooth enabled and improves the adherence to prescribed therapy along with track MDI (Metered-dose inhaler) usage of patients with chronic respiratory diseases.
In February 2020, BD (Becton, Dickinson and Company), a significant global medical technology company, made an announcement of the completion of a 50-subject human clinical trial by using ‘BD Libertas Wearable Injector’.
Such brave and encouraging initiatives taken by the global market players have enhanced the growth of the connected drug delivery market during the pandemic.